LymphedemaV1, PubMed, Curation, bibRecord, 000613

The Impact of L-Dex(®) Measurements in Assessing Breast Cancer-Related Lymphedema as Part of Routine Clinical Practice.

Identifieur interne : 000613 ( PubMed/Curation ); précédent : 000612; suivant : 000614

The Impact of L-Dex(®) Measurements in Assessing Breast Cancer-Related Lymphedema as Part of Routine Clinical Practice.

Auteurs : Alison Laidley [États-Unis] ; Beth Anglin [États-Unis]

Source :

Frontiers in oncology [ 2234-943X ] ; 2016.

RBID : pubmed:27656420

Abstract

With improved survivorship, the prevalence of breast cancer-related lymphedema (BCRL) continues to increase, leading to impairment of a patients' quality of life. While traditional diagnostic methods are limited by an inability to detect BCRL until clinically apparent, bioimpedance spectroscopy (BIS) has been shown to detect subclinical BCRL. The purpose of this study is to evaluate the role of BIS in the early detection of BCRL, as well as assessment of response to BCRL treatment.

DOI: 10.3389/fonc.2016.00192
PubMed: 27656420

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000613

Links to Exploration step

pubmed:27656420

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Impact of L-Dex(®) Measurements in Assessing Breast Cancer-Related Lymphedema as Part of Routine Clinical Practice.</title>
<author><name sortKey="Laidley, Alison" sort="Laidley, Alison" uniqKey="Laidley A" first="Alison" last="Laidley">Alison Laidley</name>
<affiliation wicri:level="1"><nlm:affiliation>Texas Oncology, Texas Breast Specialists , Dallas, TX , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Texas Oncology, Texas Breast Specialists , Dallas, TX </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Anglin, Beth" sort="Anglin, Beth" uniqKey="Anglin B" first="Beth" last="Anglin">Beth Anglin</name>
<affiliation wicri:level="1"><nlm:affiliation>North Texas Surgical Oncology Associates , Plano, TX , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>North Texas Surgical Oncology Associates , Plano, TX </wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27656420</idno>
<idno type="pmid">27656420</idno>
<idno type="doi">10.3389/fonc.2016.00192</idno>
<idno type="wicri:Area/PubMed/Corpus">000613</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000613</idno>
<idno type="wicri:Area/PubMed/Curation">000613</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000613</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The Impact of L-Dex(®) Measurements in Assessing Breast Cancer-Related Lymphedema as Part of Routine Clinical Practice.</title>
<author><name sortKey="Laidley, Alison" sort="Laidley, Alison" uniqKey="Laidley A" first="Alison" last="Laidley">Alison Laidley</name>
<affiliation wicri:level="1"><nlm:affiliation>Texas Oncology, Texas Breast Specialists , Dallas, TX , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Texas Oncology, Texas Breast Specialists , Dallas, TX </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Anglin, Beth" sort="Anglin, Beth" uniqKey="Anglin B" first="Beth" last="Anglin">Beth Anglin</name>
<affiliation wicri:level="1"><nlm:affiliation>North Texas Surgical Oncology Associates , Plano, TX , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>North Texas Surgical Oncology Associates , Plano, TX </wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Frontiers in oncology</title>
<idno type="ISSN">2234-943X</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">With improved survivorship, the prevalence of breast cancer-related lymphedema (BCRL) continues to increase, leading to impairment of a patients' quality of life. While traditional diagnostic methods are limited by an inability to detect BCRL until clinically apparent, bioimpedance spectroscopy (BIS) has been shown to detect subclinical BCRL. The purpose of this study is to evaluate the role of BIS in the early detection of BCRL, as well as assessment of response to BCRL treatment.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27656420</PMID>
<DateCreated><Year>2016</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>09</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>6</Volume>
<PubDate><Year>2016</Year>
</PubDate>
</JournalIssue>
<Title>Frontiers in oncology</Title>
<ISOAbbreviation>Front Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>The Impact of L-Dex(®) Measurements in Assessing Breast Cancer-Related Lymphedema as Part of Routine Clinical Practice.</ArticleTitle>
<Pagination><MedlinePgn>192</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2016.00192</ELocationID>
<Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">With improved survivorship, the prevalence of breast cancer-related lymphedema (BCRL) continues to increase, leading to impairment of a patients' quality of life. While traditional diagnostic methods are limited by an inability to detect BCRL until clinically apparent, bioimpedance spectroscopy (BIS) has been shown to detect subclinical BCRL. The purpose of this study is to evaluate the role of BIS in the early detection of BCRL, as well as assessment of response to BCRL treatment.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective review of 1,133 patients treated between November 2008 and July 2013 at two surgical practices was performed. Eligible patients (n = 326) underwent preoperative and postoperative L-Dex measurements. Patients were identified as having subclinical lymphedema if they were asymptomatic and the L-Dex score increased >10 U above baseline and were monitored following treatment. Patients were stratified by lymph node dissection technique [sentinel lymph node biopsy (SLNB) vs. axillary lymph node dissection (ALND)] and receipt of BCRL treatment.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The average age of the cohort was 56.2 years old, and mean follow-up was 21.7 months. Of the 326 patients, 210 underwent SLNB and 116 underwent ALND. BCRL was identified by L-Dex in 40 patients (12.3%). The cumulative incidence rate of subclinical lymphedema was 4.3% for SLNB (n = 9) and 26.7% for ALND (n = 31). Of those diagnosed with BCRL, 50% resolved following treatment, 27.5% underwent treatment without resolution, and 22.5% had resolution without treatment. The prevalence of persistent, clinical BCRL was 0.5% for SLNB and 8.6% for ALND.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrates both the feasibility and clinical utility of implementing L-Dex measurements in routine breast cancer care. L-Dex identified patients with possible subclinical BCRL and allowed for assessment of response to therapy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laidley</LastName>
<ForeName>Alison</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Texas Oncology, Texas Breast Specialists , Dallas, TX , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Anglin</LastName>
<ForeName>Beth</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>North Texas Surgical Oncology Associates , Plano, TX , USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>09</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Front Oncol</MedlineTA>
<NlmUniqueID>101568867</NlmUniqueID>
<ISSNLinking>2234-943X</ISSNLinking>
</MedlineJournalInfo>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 1999 Oct;178(4):311-5</RefSource>
<PMID Version="1">10587190</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2014 Dec;12(4):289-94</RefSource>
<PMID Version="1">25495384</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2005;3(4):208-17</RefSource>
<PMID Version="1">16379589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Breast Cancer. 2012 Apr;12(2):133-7</RefSource>
<PMID Version="1">22444720</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2008 Jun 15;112(12):2809-19</RefSource>
<PMID Version="1">18428212</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Jul 20;26(21):3536-42</RefSource>
<PMID Version="1">18640935</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2006 Nov;192(5):636-9</RefSource>
<PMID Version="1">17071198</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CA Cancer J Clin. 2009 Jan-Feb;59(1):8-24</RefSource>
<PMID Version="1">19147865</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Angiology. 2002 Jan-Feb;53(1):41-7</RefSource>
<PMID Version="1">11863308</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 2010 Jan 12;340:b5396</RefSource>
<PMID Version="1">20068255</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg. 2007 Mar;245(3):452-61</RefSource>
<PMID Version="1">17435553</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lymphology. 2001 Mar;34(1):2-11</RefSource>
<PMID Version="1">11307661</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lymphology. 2010 Sep;43(3):118-27</RefSource>
<PMID Version="1">21226414</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2011;16(10):1367-79</RefSource>
<PMID Version="1">21964004</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):85-90</RefSource>
<PMID Version="1">19427748</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2002 May;73(1):31-6</RefSource>
<PMID Version="1">12083629</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Invest. 2010 Jan;28(1):54-62</RefSource>
<PMID Version="1">19916749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>QJM. 2005 May;98(5):343-8</RefSource>
<PMID Version="1">15820971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Support Care Cancer. 2013 Aug;21(8):2207-15</RefSource>
<PMID Version="1">23494582</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lymphology. 2004 Jun;37(2):73-91</RefSource>
<PMID Version="1">15328760</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2010;49(2):166-73</RefSource>
<PMID Version="1">20100154</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2003 Aug 7;349(6):546-53</RefSource>
<PMID Version="1">12904519</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Apr 20;27(12):2007-14</RefSource>
<PMID Version="1">19289624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2005 Oct 1;92(1):23-31</RefSource>
<PMID Version="1">16180231</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):907-14</RefSource>
<PMID Version="1">21945108</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2002 Sep;75(1):51-64</RefSource>
<PMID Version="1">12500934</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2015 Mar;13(1):40-5</RefSource>
<PMID Version="1">25526543</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66</RefSource>
<PMID Version="1">17237035</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<OtherID Source="NLM">PMC5011139</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALND</Keyword>
<Keyword MajorTopicYN="N">BCRL</Keyword>
<Keyword MajorTopicYN="N">BIS</Keyword>
<Keyword MajorTopicYN="N">L-Dex</Keyword>
<Keyword MajorTopicYN="N">SLNB</Keyword>
<Keyword MajorTopicYN="N">bioimpedance</Keyword>
<Keyword MajorTopicYN="N">breast cancer</Keyword>
<Keyword MajorTopicYN="N">lymphedema</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>06</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>08</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>9</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>9</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>9</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27656420</ArticleId>
<ArticleId IdType="doi">10.3389/fonc.2016.00192</ArticleId>
<ArticleId IdType="pmc">PMC5011139</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000613 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000613 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:27656420
   |texte=   The Impact of L-Dex(®) Measurements in Assessing Breast Cancer-Related Lymphedema as Part of Routine Clinical Practice.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:27656420" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

The Impact of L-Dex(®) Measurements in Assessing Breast Cancer-Related Lymphedema as Part of Routine Clinical Practice.

The Impact of L-Dex(®) Measurements in Assessing Breast Cancer-Related Lymphedema as Part of Routine Clinical Practice.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki